---

＜電子ブック＞
Phase II Clinical Development of New Drugs / by Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri
(ICSA Book Series in Statistics. ISSN:21990999)

版	1st ed. 2017.
出版者	(Singapore : Springer Nature Singapore : Imprint: Springer)
出版年	2017
大きさ	XVII, 241 p. 25 illus., 17 illus. in color : online resource
著者標目	*Ting, Naitee author Chen, Ding-Geng author Ho, Shuyen author Cappelleri, Joseph C author SpringerLink (Online service)
件　名	LCSH:Biometry LCSH:Pharmaceutical chemistry LCSH:Management FREE:Biostatistics FREE:Pharmaceutics FREE:Management
一般注記	Chapter 1 Introduction -- Chapter 2 Concept of Alpha -- Chapter 3 Confirmation and Exploration -- Chapter 4 Design a Proof of Concept (PoC) Trial -- Chapter 5 Design of Dose-Ranging Trials -- Chapter 6 Combining PoC and Dose Ranging Trials -- Chapter 7 Risks of Inconclusiveness -- Chapter 8 Analysis of a PoC Study -- Chapter 9 Data Analysis for Dose-Ranging Trials with Continuous Outcome -- Chapter 10 Data Analysis of Dose-Ranging Trials for Binary Outcomes -- Chapter 11 Bayesian Methods -- Chapter 12 Overview of Phase III Clinical Trials This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them HTTP:URL=https://doi.org/10.1007/978-981-10-4194-5

 類似資料